The European Medicines Agency this week recommended pan-EU approval for eight medicines including Vertex Pharmaceuticals’ triple combination therapy for cystic fibrosis. Once approved, the elexacaftor/tezacaftor/ivacaftor combination will become Europe’s first such therapy for many CF patients.
Branded Trikafta in the US, where it was approved in October 2019, the combination will be sold under the brand...








